BVM Capital

BVM Capital, LLC was a venture capital and private equity firm based in Bossier City, Louisiana, with additional offices in New York and New Orleans. Established in 2003, the firm specialized in early and expansion stage investments, primarily focusing on life sciences, healthcare, technology, biotechnology, and pharmaceuticals. BVM Capital aimed to support companies in the Southeast, particularly in Louisiana, by investing equity ranging from $0.1 million to $3 million. The firm typically sought a board seat in its portfolio companies and generally held investments for three to seven years, looking to exit through mergers, acquisitions, or initial public offerings. BVM Capital is no longer operational.

Ross Barrett

Co-Founder & Managing Partner

7 past transactions

Embera NeuroTherapeutics

Series A in 2015
Embera NeuroTherapeutics is a development stage pharmaceutical company focused on developing treatments for smoking cessation and other addictions, for which there are a limited range of effective drug therapies or have no approved treatments. Embera is developing a novel addiction treatment (EMB-001) that targets specific and complementary brain functions that drive the craving and relapse associated with these disorders, an approach based on breakthrough discoveries of the scientific founder.

Microbiome Therapeutics

Seed Round in 2013
MicroBiome Therapeutics, LLC is a biotechnology company based in Broomfield, Colorado, founded in 2009. The company specializes in developing medical food and pharmaceutical products that act as microbiome modulators, aimed at altering bacterial populations and their environment in the gastrointestinal tract to treat and prevent serious health conditions. One of its notable products, NM504, combines prebiotic ingredients with other naturally occurring components to assist individuals with diabetes in maintaining healthy blood glucose levels and managing body weight. The company's formulations include fermentable fiber and polyphenol antioxidants, designed to promote the growth of beneficial bacteria while inhibiting harmful strains, thereby supporting overall health.

K94 Discoveries

Seed Round in 2013
K94 Discoveries, Inc. operates as a biotechnology company and develops anticancer drugs based on discoveries by scientists at LSU’s Pennington Biomedical Research Institute and Feist Weiller Cancer Center. The company is based in the United States.

FIX Health

Seed Round in 2012
FIX Health develops high quality, interactive games that promote health and daily activity in a fun. FIX is dedicated to making fitness fun, accessible and hyper-socially connected through an interactive social media platform centered around making the pursuit of fitness an enjoyable and engaging game.

NuMe Health

Series A in 2012
NuMe Health is a biotechnology company focused on medical foods for the special dietary requirements associated with major chronic diseases including: cancer, obesity, and diabetes.

NuMe Health

Series A in 2011
NuMe Health is a biotechnology company focused on medical foods for the special dietary requirements associated with major chronic diseases including: cancer, obesity, and diabetes.

Calosyn Pharma

Seed Round in 2009
CaloSyn Pharma, Inc. is a biopharmaceutical company focused on developing intra-articular therapeutics specifically for osteoarthritis (OA), a condition affecting over 27 million people in the United States and more than 100 million globally. Founded in 2007 and headquartered in Boston, Massachusetts, with additional offices in Shreveport, Louisiana, and Atlanta, Georgia, the company is advancing a novel approach to OA treatment through the use of calcium channel blockers, drugs traditionally employed in heart and vascular disease management. By leveraging new insights into the mechanisms of these drugs and the processes underlying joint damage and pain in osteoarthritis, CaloSyn Pharma aims to reformulate and repurpose these medications for direct injection into affected joints. The company is currently conducting a Phase II clinical trial in the United States to evaluate the efficacy of its therapeutic approach.